And seemingly uses machine learning to explain why it’s kinda not but kinda is
IBM Watson Health is tapering off its Drug Discovery program, which uses «AI» software to help companies develop new pharmaceuticals, blaming poor sales.
The service isn’t completely shutting down, however. IBM spokesperson Ed Barbini told The Register: “We are not discontinuing our Watson for Drug Discovery offering, and we remain committed to its continued success for our clients currently using the technology. We are focusing our resources within Watson Health to double down on the adjacent field of clinical development where we see an even greater market need for our data and AI capabilities.
